


Cell Marque™ Tissue Diagnostics

IMMUNOHISTOCHEMISTRY and GASTROINTESTINAL CARCINOMAS

Mike Lacey, M.D.



Gastrointestinal (GI) Pathology





Immunohistochemistry and Gastrointestinal Carcinomas

Mike Lacey, M.D.

In the past 25 years, the technique of immunohistochemistry has become a near-routine procedure in the assessment of many malignancies involving the GI tract. This technique is useful in various determinations, not the least of which is the origin of a malignancy in the setting of metastatic disease. The following is an effort to summarize the more useful aspects of that collective knowledge.*

OVERVIEW OF COLORECTAL CANCER

Incidence

In both men and women, colorectal cancer is the third most commonly diagnosed cancer in the United States (excluding skin cancers). Colorectal cancer incidence rates have been decreasing for most of the past two decades (from 66.3 cases per 100,000 persons in 1985 to 45.5 cases in 2006). This has been attributed to increases in the use of colorectal screening tests that allow the detection and removal of colorectal polyps before the progress to cancer. In contrast to overall declines, among adults younger than 50 years, for whom screening is not recommended for those at average risk, colorectal cancer incidence rates have been increasing by about 2% per year since 1994 in both men and women.¹

Deaths

An estimated 49,500 deaths from colorectal cancer are expected in 2016 in the U.S. Mortality rates for colorectal cancer have declined in both men and women over the past few decades, with steeper declines in the most recent time period. This decrease reflects declining incidence rates and improvements in early detection and treatment.¹

Signs and symptoms

Early stage colorectal cancer does not usually have symptoms; therefore, screening is often necessary to detect colorectal cancer in its early stages. Advanced disease may cause rectal bleeding, blood in the stool, a change in bowel habits, and cramping pain in the lower abdomen.¹

IMMUNOHISTOCHEMISTRY AND COLON CANCER


Immunohistochemical applications surrounding colon cancer are seen at several levels such as: characterization of the tumor (endocrine or epithelial type), hereditary disposition, and for prognostic purposes. The more prevalent use of IHC is in the presence of possible or suspected metastatic disease in which the colon is a possible primary. The common locations for metastases from colon cancers are the liver and lung; both organs of which can produce cancer morphology essentially identical to metastases from the colon. IHC, in a Class I regulations, is used after the primary diagnosis of the tumor has been identified through histopathology and not intended to be reported to clinicians as independent findings.

Gastrointestinal Tract Adenocarcinomas VS. Other

	CK 7	CK 20	SATB2	CDX-2	Cadherin-17	Hep Par-1	Napsin A	P504s	GATA3	S100P
Colorectal Adenocarcinoma	-	+	+	+	+	-	-	-	-	-
Gastric Adenocarcinoma	+/-	+/-	-	+	-	-	-	-	-	-
Esophageal Adenocarcinoma	+/-	+/-	-/+	+/-	+	-	-	-	-	-
Gastrointestinal Stromal Tumor	-	-	-	-	-	-	-	-	-	-
Pancreatic Ductal Adenocarcinoma	+	+	-	-/+	-	-	-	-	-	+
Hepatocellular Carcinoma	-	-	-	-	-	+	-	-	-	-
Lung Adenocarcinoma	+	-	-	-	-	-	+	-	-	-
Breast Carcinoma	+	-	-	-	-	-	-	-	+	-
Prostatic Adenocarcinoma	-	-	-	-	-	-	-	+	-	-
Urothelial Carcinoma	+	+	-	-	-	-	-	-	+	+
Ovarian Carcinoma	-/+	+/-	-	-	-	-	-	-	-	-

carcinoma

Diagnostic Panel



Metastatic Carcinoma

The most common use of immunohistochemistry in the study of liver tumors is to identify the site of origin of a metastatic tumor when the primary site has not yet been identified. The development and implementation of a panel of immunostains can help resolve almost all diagnostic problems.²⁻⁶ Cytokeratin (CK) 7 and CK 20 are the first step in the immunohistochemical identification of many tumors, and with additional immunostains, some relatively specific for tumors of males and of females, one is able to identify potential sites of origin.³


STOMACH

Immunohistochemical studies are generally not needed for the evaluation of benign and malignant epithelial tumors of the stomach because the histopathology is generally diagnostic but are used in the study of metastatic gastric carcinoma when the site of origin is not clear or when the macroscopic/radiologic appearance of the tumor is confusing (eg, gastric carcinoma directly and massively invading the liver and histologically indistinguishable from cholangiocarcinoma). In addition, immunohistochemistry is useful for the identification of some variants of gastric carcinomas including hepatoid adenocarcinomas in which hepatostic differentiation can be confirmed by positivity for alpha feto-protein (AFP).⁷

Adenocarcinoma

Gastric adenocarcinomas will react with many antibodies directed against keratins, including AE1 & AE3, CK 35betaH11, CK 18, CK 19, CK 7, and CK 20. When CK 7 and CK 20 are used together, many gastric adenocarcinomas will stain with both CK 7 and CK 20.^{5,8-10} Approximately 25% will be positive for one and negative for the other (eg, CK 7+/CK 20-, CK 7-/CK 20+), and a small number of cases will be negative for both. CDX-2, initially thought to be specific for colon carcinoma, will be reactive in more than 50% of cases¹¹⁻¹² and may be indicative of a lesser degree of invasiveness.¹³⁻¹⁴ Even Hep Par-1, a useful marker for hepatocytes, will be

positive in more than 50% of gastric cancers, including signet-ring cell carcinoma.¹⁵ The quantity and quality of mucus production by gastric carcinoma, as evaluated by immunohistochemical study of mucins, may be prognostically important; MUC2 expression is associated with poor survival.¹⁶



Ki-67 (SP6)

Neuroendocrine Carcinoma

Neuroendocrine carcinoma characteristically stains with synaptophysin, chromogranin, villin, and CD57.¹⁷⁻¹⁸ In contrast to gastric adenocarcinoma, carcinomas occurring in the second part of the duodenum may be negative for both synaptophysin and

chromogranin but will often react with somatostatin. The proliferation marker Ki-67 and the adhesion molecule E-cadherin have been used to assess aggressiveness of neuroendocrine carcinoma.¹⁹ An increased Ki-67 proliferation index (< or =2%, 3-20% and >20% for G1, G2, and G3 lesions respectively)²⁰ predicts aggressive behavior, and loss of E-cadherin may predict lymph node metastasis.

Gastrointestinal Adenocarcinoma with Neuroendocrine Differentiation

Gastric adenocarcinomas, both intestinal type and signet-ring cell type, can have neuroendocrine differentiation that may not be obvious with hematoxylin-eosin staining but will show staining with chromogranin and/or synaptophysin.²¹

GASTROINTESTINAL STROMAL TUMORS

CD117 stains most cases of gastrointestinal stromal tumor, including metastases.²¹⁻²⁵ Although there may

sometimes be variation in distribution of CD117 positivity within a given tumor, in most cases staining is diffuse. When CD117 is positive in tumors other than gastrointestinal stromal tumor, the staining is almost always patchy. CD34 staining can also be seen in gastrointestinal stromal tumor. 10 to 15% of GIST are negative for CD117. DOG1 antibody has been shown to label the majority of CD117 negative GISTs.²⁶ In addition, loss of SDHB has been proven to be consistent feature of SDH-deficient GISTs, thereby being helpful for the identification of this disease variant.²⁷

GIST Mutation vs. Wild Type

	CD34	CD117	DOG1
GIST, Kit Mutation	+	+	+
GIST, PDGFRA Mutation	-	-	+
GIST, Wild Type	+/-	+	+


COLON

Adenomas and Adenocarcinoma

Adenomas (tubular adenoma, tubulovillous adenoma, villous adenoma) demonstrate the same immunohistochemical reactions as colonic adenocarcinoma. Almost all react with antibody directed against CK 20 and a minority will also stain focally with CK 7, in contrast to pancreatic adenocarcinomas, most of which are CK 20 negative and CK 7 positive. Differentiation of metastatic colorectal adenocarcinoma from adenocarcinoma arising at other sites can sometimes be challenging. Pulmonary adenocarcinoma can resemble colorectal adenocarcinoma. CK 7 and CK 20 can be helpful in this regard, with CK 7 usually strongly positive in lung adenocarcinomas and CK 20 usually negative; the reverse pattern is seen with colorectal adenocarcinoma. In addition, thyroid transcription factor 1 (TTF-1) is generally positive in lung cancers, and CDX-2 and beta-catenin are generally positive in colorectal cancers. Endometrioid-type carcinomas can also be histologically indistinguishable from colorectal carcinoma. Here, again, CK 7 is positive in almost all endometrioid adenocarcinomas and only mildly reactive in colorectal adenocarcinomas. CK 20 is generally negative for lung primaries but positive for colorectal.

Appendiceal Adenocarcinoma

Appendiceal adenocarcinoma will typically show staining for MUC5AC, in contrast to colonic adenocarcinoma in which this antibody is rarely reactive.²⁸⁻²⁹ This is particularly useful in studying mucinous adenocarcinomas



MUC5AC (MRQ-19)


that have metastasized in the abdomen. Beta-Catenin is another differentiating antibody, positive in almost all colonic adenocarcinomas and negative in appendiceal adenocarcinomas. In women with abdominal mucinous carcinomatosis, distinction of colonic and appendiceal adenocarcinoma from

ovarian adenocarcinoma is important. In colonic tumors, both villin and beta-catenin are often expressed; in appendiceal metastases villin is often expressed, but beta-catenin is unusual and in ovarian mucinous adenocarcinomas neither villin nor beta-catenin are seen.³⁰ Similar to appendiceal lesions, ovarian carcinomas express MUC5AC and similar to colorectal adenocarcinoma, ovarian mucinous adenocarcinomas express CDX-2. Useful supplements to the basic panels for unknown primaries in which appendiceal or ovarian mucinous tumors are suspected are MUC5AC and beta-catenin. Villin can also be helpful because it typically has a "brush-border" pattern of staining in both colonic and appendiceal adenocarcinoma and is typically cytoplasmic in ovarian and pancreatic lesions.³¹


PANCREAS

Invasive Ductal Adenocarcinoma


Adenocarcinoma of the pancreas usually derives from precursor stages of pancreatic ductal dysplasia. The immunostaining pattern of high-grade pancreatic intraepithelial neoplasia is the same as that of invasive pancreatic adenocarcinoma and cannot be used to differentiate between them. Pancreatic ductal adenocarcinomas resemble adenocarcinomas of the bile ducts and gallbladder in their light microscopy appearances and also in their immunophenotypical presentations. Pancreatic adenocarcinomas react with a variety of keratin antibodies, including CK 8, CK 17, CK 18, CK 19, CAM 5.2, and AE1 & AE3.^{5,32} Pancreatic adenocarcinoma is generally both CK 7 and CK 20 positive. Pancreatic adenocarcinoma can also be faintly CDX-2 positive.^{4,11} Almost all pancreaticobiliary adenocarcinomas are CEA positive and CA-125 positive. They may also have a minor component of neuroendocrine cells, which will react with somatostatin, synaptophysin, chromogranin, or other neuroendocrine markers.³³ Therapy outcomes can also be predicted with




Cytokeratin (35betaH11)



Cytokeratin 19 (A53-B/A2.26)



Cytokeratin (CAM 5.2)



Cytokeratin Cocktail (AE1 & AE3)


positive vascular endothelial growth factor and negative SMAD4 (DPC4) immunostaining.³⁴ Loss of expression of SMAD4 has also been shown in bile duct epithelium in cases of chronic gallstone disease.³⁵ Well-differentiated metastatic pancreatic carcinoma to the liver may be difficult to distinguish from benign bile duct lesions in biopsy material. Unlike the benign lesions, however, they typically express p53, cytoplasmic mCEA, and other markers including CA-125.³⁶

Neuroendocrine and Endocrine Cell Tumors, Low Grade and High Grade

Low- and high-grade neuroendocrine tumors tend to show similar immunophenotypic expressions, but, in general, the intensity of staining is less with high-grade tumors. They can be grouped by the predominant secreted hormone (eg, somatostatin, gastrin) but usually also stain with synaptophysin and chromogranin, as well as with various keratins, including CK 8, CK 18, and CK 35betaH11. CK 7 and CK 20 are generally negative.³⁷⁻⁴¹ CD56 and CD57 tend to stain more intensely in high-grade neuroendocrine tumors than in low-grade, in a membranous pattern; CD56 will also be positive in a variety of other

CD56 and CD57 tend to stain more intensely in high-grade neuroendocrine tumors than in low-grade, in a membranous pattern.

tumors.³⁷⁻⁴² Serotonin can also be demonstrated.⁴³ High-grade neuroendocrine tumors can also stain with calcitonin, and metastatic lesions can be misinterpreted as having arisen in the thyroid.⁴¹ Epithelial cytoplasmic expression of CD10, in contrast to membrane staining, is more commonly seen in malignant than in benign pancreatic endocrine tumors.⁴⁴



SATB2 (EP281)

SATB2

Special AT-rich sequence-binding protein 2 (SATB2) is a recently described marker that functions as a nuclear matrix-associated transcription factor. It has been reported that SATB2, in combination with CK20, could identify almost all colorectal carcinomas,⁴⁵ including poorly differentiated colorectal

carcinomas.⁴⁶ Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2,⁴⁵ and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive

for SATB2.⁴⁵⁻⁴⁶ Therefore, SATB2 is a good marker for identifying a carcinoma of colorectal origin when working on a tumor of unknown primary.⁴⁵⁻⁴⁷ Another potential utility of SATB2 is to identify neuroendocrine neoplasms/ carcinomas of the left colon and rectum because SATB2 is usually negative in other neuroendocrine neoplasms of the GI tract, pancreas, and lung.⁴⁸

REFERENCES

1. American Cancer Society
2. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. *Hum Pathol.* 2002;33:1175-1181.
3. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. *Cancer.* 1999;85:171-177.
4. Tot T. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20_/7- phenotype. *Med Sci Monit.* 2004;10:BR139-BR143.
5. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. *Appl Immunohistochem.* 1995;3:99-107.
6. Rullier A, Le Bail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastases. *Am J Surg Pathol.* 2000;24:870-876.
7. Inagawa S, Shimazaki J, Hori M, Yoshimi F, Adachi S, et al. Hepatoid adenocarcinoma of the stomach. *Gastric Cancer* 2001; 4:43-52.
8. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. *Histopathology.* 2003;42:1137-1140.
9. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratin 7 and 20 in arcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. *Hum Pathol.* 2002;33:1078-1085.
10. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. *Mod Pathol.* 2000;13:962-972.
11. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. *Am J Surg Pathol.* 2003;27:303-310.
12. Moskaluk CA, Zhang H, Powell SM, et al. CDX2 protein expression in normal and malignant human tissues: immunohistochemical survey using tissue microarrays. *Mod Pathol.* 2003;16:913-919.
13. Ha Kim G, Am Song G, Youn Park D, et al. CDX2 expression is increased in gastric cancers with less invasiveness and intestinal mucin phenotype. *Scand J Gastroenterol.* 2006;41:880-886.
14. Roessler K, Monig SP, Schneider PM, et al. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlation with clinico-pathologic parameters and prognosis. *World J Gastroenterol.* 2005;11:3182-3188.
15. Fan Z, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. *Mod Pathol.* 2003;16:137-144.
16. Leteurtre E, Zerimech F, Piessen G, et al. Relationships between mucinous gastric carcinoma, MUC2 expression and survival. *World J Gastroenterol.* 2006;7:3324-3331.
17. Burke AP, Thomas RM, Elsayed AM, et al. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. *Cancer.* 1997;79:1086-1093.
18. Park JG, Choe GY, Helman LJ, et al. Chromogranin-A expression in gastric and colon cancer tissues. *Int J Cancer.* 1992;51:189-194.
19. Boo YJ, Park SS, Kim JH, et al. Gastric neuroendocrine carcinoma: clinicopathologic

review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers. *J Surg Oncol.* 2007;95:110-117.

20. Rindi G, Arnold R, Bosman F. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman T, Carneiro F, Hruban R, Theise N, eds. WHO classification of tumours of the digestive system. Lyon, France: International Agency for Research on Cancer, 2010:13-14
21. Blumenfeld W, Chandhoke DK, Sagerman P, et al. Neuroendocrine differentiation in gastric adenocarcinomas: an immunohistochemical study. *Arch Pathol Lab Med.* 1996;120:478-481.
22. Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathologic and immunohistochemical study of 108 resected cases of the stomach. *Histopathology.* 2003;43:118-126.
23. Greenson JK. Gastrointestinal stromal tumors and other mesenchymal tumors of the gut. *Mod Pathol.* 2003;16:366-375.
24. Goldblum JR. Gastrointestinal stromal tumors: a review of characteristic morphologic, immunohistochemical, and molecular genetic features. *Am J Clin Pathol.* 2002;117(suppl):S49-S61.
25. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. *Pathol Oncol Res.* 2003;9:13-19
26. West RB, Corless CL, Chen X, et al. The Novel Marker, DOG1, is expressed ubiquitously in Gastrointestinal Stromal Tumors irrespective of KIT or PDGFRA mutation status. *Am J Pathol* 2004, 165:107-113
27. Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors (GISTs) - A Review. *Int J Biochem Cell Biol.* 2014; 0:514-519.
28. Lee MJ, Lee HS, Kim WH, et al. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. *Mod Pathol.* 2003;16:403-410.
29. Albarracin CT, Jafri J, Montag AG, et al. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colon carcinoma. *Hum Pathol.* 2000;31:672-677.
30. Chou YY, Jeng YM, Kao HL, et al. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. *Histopathology.* 2003;43:151-156.
31. Nishizuka S, Chen ST, Gwadry FG, et al. Diagnostic markers than distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. *Cancer Res.* 2003;63:5243-5250.
32. Yamaguchi K, Enjoji M. Carcinoma of the pancreas: a clinicopathologic study of 96 cases with immunohistochemical observation for CEA and CA19-9. *J Surg Oncol.* 1991;47:148-154.
33. Tamiolakis D, Simopoulos C, Venizolos J, et al. Distribution of somatostatin in pancreatic ductal adenocarcinoma remodels the normal pattern of the protein during foetal pancreatic development: an immunohistochemical analysis. *Clin Exp Med.* 2005;5:106-111.
34. Khorana AA, Hu YC, Ryan CK, et al. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. *J Gastrointest Surg.* 2005;9:903-911.
35. Lee KT, Chang WT, Wang SN, et al. Expression of DPC4/Smad4 gene in stone-containing intrahepatic bile duct. *J Surg Oncol.* 2006;15:94:338-343.
36. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. *Am J Surg Pathol.* 2005;29:381-389.
37. Mertz H, Vyberg M, Paulsen SM, et al. Immunohistochemical detection of neuroendocrine markers in tumors of the lungs and gastrointestinal tract. *Appl Immunohistochem.* 1998;6:175-180.
38. Bordi C, Yu JY, Baggi MT, et al. Gastric carcinoids and their precursor lesions: a histologic and immunohistochemical study of 23 cases. *Cancer.* 1991;67:663-672.
39. Lam KY, Lo CY. Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. *Eur J Surg Oncol.* 1997;23:36-42.
40. Rindi G, Paolotti D, LaRosa S, et al. The tumours of the endocrine pancreas. *Eur J Histochem.* 1998;42:63-66.
41. Chetty R, Asa SL. Pancreatic endocrine tumors. *Adv Anat Pathol.* 2004;22:202-210.
42. Shipley WR, Hammer RD, Lennington WJ, et al. Paraffin immunohistochemical detection of CD56, a useful marker for neural cell adhesion molecule (NCAM), in normal and neoplastic fixed tissues. *Appl Immunohistochem.* 1997;5:87-93.
43. Soga J. Carcinoids of the pancreas: an analysis of 156 cases. *Cancer.* 2005;104:1180-1187.
44. Deschamps L, Handra-Luca A, O'Toole D, et al. CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. *Hum Pathol.* 2006;37:802-808.
45. Mangnusso K, et al. SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. *Am J Surg Pathol.* 2011; 35:937-948.
46. Lin F, et al. Cadherin-17 and SATB2 Are Sensitive and Specific Immunomarkers for Medullary Carcinoma of the Large Intestine. *Arch Pathol Lab Med.* 2014; 138:1015-26.
47. Dragomir A, et al. The Role of SATB2 as a Diagnostic Marker for Tumors of Colorectal Origin. *Am J Clin Pathol* 2014; 141:630-38.
48. Li Z, et al. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors. *Mod Pathol.* 2013; 26:164A.

*Cell Marque™ products are designated as Class I medical devices. These products are to provide the pathologist with adjunctive diagnostic information that may be incorporated into the pathologist's report, but that is not ordinarily reported to clinicians as an independent finding. Cell Marque™ assumes no liability for the information reported through peer review literature. It is the sole responsibility of the laboratories to independently validate the application and proper use of any product(s) described in this article.

The contents of this article is intended for educational purposes and should be used as a guideline only.

The antibody panels were constructed based on the internal investigations of Cell Marque™ with scores based on the percentage of positivity represented as follows: "-" for 0-40%, "-/+" for 40-50%, "+/-" for 50-60%, "+" for 60-100%, and blank for no available data.

Cell Marque™ Tissue Diagnostics

Toll-Free: 800.665.7284 • 916.746.8900 • Fax: 916.746.8989

www.cellmarque.com • service@cellmarque.com

©2017 Sigma-Aldrich Co. LLC. All rights reserved. Cell Marque is a trademark of Sigma-Aldrich Co. LLC. Sigma-Aldrich Co., LLC is a subsidiary of Merck KGaA, Darmstadt, Germany.